Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Mylan NV (NASDAQ:MYL) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 59,180 shares of the company’s stock, valued at approximately $1,622,000.
Several other large investors have also added to or reduced their stakes in MYL. First Hawaiian Bank raised its holdings in shares of Mylan by 560.4% in the 4th quarter. First Hawaiian Bank now owns 2,886 shares of the company’s stock valued at $79,000 after acquiring an additional 2,449 shares in the last quarter. NuWave Investment Management LLC increased its position in shares of Mylan by 18.1% during the 4th quarter. NuWave Investment Management LLC now owns 3,136 shares of the company’s stock valued at $86,000 after purchasing an additional 480 shares during the last quarter. FNY Investment Advisers LLC increased its position in shares of Mylan by 42.8% during the 4th quarter. FNY Investment Advisers LLC now owns 3,300 shares of the company’s stock valued at $90,000 after purchasing an additional 989 shares during the last quarter. Quantamental Technologies LLC bought a new position in shares of Mylan during the 4th quarter valued at about $100,000. Finally, Huntington National Bank increased its position in shares of Mylan by 200.4% during the 4th quarter. Huntington National Bank now owns 3,860 shares of the company’s stock valued at $106,000 after purchasing an additional 2,575 shares during the last quarter. 83.01% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts have recently commented on MYL shares. Argus upgraded Mylan from a “hold” rating to a “buy” rating and set a $42.00 price objective on the stock in a research report on Thursday, November 15th. Cantor Fitzgerald reiterated a “hold” rating and set a $41.00 price objective on shares of Mylan in a research report on Tuesday, November 20th. ValuEngine lowered Mylan from a “sell” rating to a “strong sell” rating in a research report on Wednesday, November 21st. Zacks Investment Research upgraded Mylan from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a research report on Tuesday, January 8th. Finally, UBS Group lowered Mylan from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $54.00 to $32.00 in a research report on Wednesday, January 23rd. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the company. Mylan currently has an average rating of “Buy” and an average target price of $40.72.
MYL opened at $28.00 on Friday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 0.83 and a current ratio of 1.39. Mylan NV has a 1 year low of $26.00 and a 1 year high of $42.50. The company has a market cap of $14.24 billion, a P/E ratio of 6.11, a P/E/G ratio of 1.15 and a beta of 1.47.
Mylan (NASDAQ:MYL) last posted its quarterly earnings results on Tuesday, February 26th. The company reported $1.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.36 by ($0.06). Mylan had a return on equity of 19.06% and a net margin of 3.08%. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.10 billion. During the same quarter in the previous year, the business earned $1.43 earnings per share. Mylan’s revenue was down 4.8% compared to the same quarter last year. Research analysts forecast that Mylan NV will post 4.38 earnings per share for the current fiscal year.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Featured Story: Municipal Bonds
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.